On May 29, 2024 ConcertAI, the leader in oncology predictive and generative AI SaaS and Real-World Data (RWD) Solutions for clinical research, reported the results of the study to be presented at the ASCO (Free ASCO Whitepaper) Annual Meeting 2024 utilizing its real-world oncology dataset (Press release, ConcertAI, MAY 29, 2024, View Source [SID1234643807]). The study, conducted in cooperation with Merck & Co., Inc., and AstraZeneca, has found earlier treatment with oliparib monotherapy may improve duration of therapy and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This real-world analysis indicates many mCRPC patients with homologous recombination repair gene mutation (HRRm) are receiving several lines of therapy prior to olaparib, even when novel hormonal agents (NHA) are used prior to mCRPC. HRRm+ patients with confirmed mCRPC diagnosis, age ≥21 years, treated with olaparib monotherapy (post May 19, 2020) and prior to abiraterone or enzalutamide were abstracted from electronic medical records in the ConcertAI Oncology Dataset with PC diagnosis between 1990 and 2023. Frequency of patients who progressed from metastatic hormone-sensitive PC (mHSPC) and from non-metastatic CRPC (nmCRPC) to mCRPC and treatment patterns prior to mCRPC were summarized.
Jeff Elton, PhD, CEO of ConcertAI stressed, "This study underscores the potential of real-world data to support specific treatment decisions and improved patient outcomes. By analyzing our vast dataset of de-identified patient records, we were able to provide compelling evidence that earlier treatment with oliparib can significantly extend the duration of therapy and overall survival for patients with metastatic castration-resistant prostate cancer. This reinforces our core mission of transforming data housed in electronic health records into actionable insights that directly benefit patient care."
This study will be presented at a poster session at the ASCO (Free ASCO Whitepaper) Annual Meeting 2024 on Sunday, June 2, between 9:00 am and 12:00 pm. Please visit poster #460 to learn more during that time. Alternatively, please visit the ConcertAI booth number 12045 at any time during exhibit hall hours.